目的 比较我院中药注射剂纳入重点监控目录措施前后的临床用药情况,分析中药注射剂重点监控管理取得的成效和不足,为临床安全合理用药及有效管理提供参考.方法 通过医院系统调取2015—2017年中药注射剂的使用数据,分析我院中药注射剂进入药品每月使用金额排名前10情况、使用金额、用药频度(DDDs)、药物的利用指数(DUI)、不良反应上报等情况.结果 2016年实施重点监控措施后中药注射剂的使用金额稳步下降,占药品总金额的比例持续降低,DUI值日趋合理,不良反应上报数量不断降低.2016年开始基本实现全部药品使用金额排名前10无中药注射剂的目标.结论 我院中药注射剂的监管措施取得了一定成效,但中药注射剂处方点评工作方式和方法有待进一步完善.%Objective To analyze the achievements and shortcomings of the key monitoring measures of traditional Chinese medicine injections (TCMI) in our hospital, by comparing the situation of clinical medication before and after putting TCMI into the key monitoring catalogue, and provide a reference for clinical safe and rational use and effective management. Methods Based on the data collected from the hospital system from 2015 to 2017, the top ten monthly usage amounts, usage amounts, DDDs, DUI and adverse reactions of TCMI in our hospital were analyzed. Results After the implementation of key monitoring measures in 2016, the use amount of TCMI has steadily decreased, the proportion of TCMI in the total amount of drugs has continued to decrease, the DUI value has become more reasonable, and the number of adverse reactions reported has been decreasing. Starting in 2016, we have basically achieved the goal of ranking the top 10 non-TCMI in the total amount of drugs used. Conclusion The regulatory measures of TCMI in our hospital achieve certain results. However, the methods of prescription evaluation of TCMI need to be further improved.
展开▼
